HRID709377

反应详情

EQUATION

反应方程式

REACTANTS

反应物

$结构：CC(=O)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C$

HCID1711945

5,9,13-Pentadecatrien-2-one, 6,10,14-trimethyl-, (5E,9E)-

C18H30O

结构：CC(=O)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)C

HCID1810797

未命名化合物

PRODUCTS

生成物

HCID1810793

未命名化合物

PROCEDURE

实验过程

Specifically, it has been found that using the R-isomer of catalyst of formula (I) in the hydrogenation of E,E-farnesylacetone (=(5E,9E)-6,10,14-trimethylpentadeca-5,9,13-trien-2-one) the hydrogenation product (6S,10S)-6,10,14-trimethylpentadecan-2-one is formed in more than 96% in respect to all of the possible stereoisomers (i.e. (6S,10S)-6,10,14-trimethylpentadecan-2-one, (6S,10R)-6,10,14-trimethylpentadecan-2-one, (6R,10S)-6,10,14-trimethylpentadecan-2-one and (6R,10R)-6,10,14-trimethylpentadecan-2-one). Hence, the corresponding (6S,10R)- and (6R,10S)- and (6R,10R)-isomers are only formed only in smaller amounts.

来源与证据

来源类型: Open Reaction Database
ORD 记录: ord-484ef40a30bf43fcbcd378750d863e41
来源数据集: uspto-grants-2015_11
DOI: 10.6084/m9.figshare.5104873.v1
专利: US09181163B2
来源说明: uspto-grants-2015_11

反应 SMILES

[CH2:1]([CH2:16][C:17](=[O:19])[CH3:18])/[CH:2]=[C:3](/[CH2:5][CH2:6]/[CH:7]=[C:8](/[CH2:10][CH2:11][CH:12]=[C:13]([CH3:15])[CH3:14])\[CH3:9])\[CH3:4].[CH3:20][C@@H:21]([CH2:28][CH2:29][CH2:30][C@@H:31]([CH3:38])[CH2:32][CH2:33][CH2:34][CH:35]([CH3:37])[CH3:36])[CH2:22][CH2:23][CH2:24][C:25](=[O:27])[CH3:26]>>[CH3:4][C@@H:3]([CH2:5][CH2:6][CH2:7][C@@H:8]([CH3:9])[CH2:10][CH2:11][CH2:12][CH:13]([CH3:15])[CH3:14])[CH2:2][CH2:1][CH2:16][C:17](=[O:19])[CH3:18].[CH3:20][C@@H:21]([CH2:28][CH2:29][CH2:30][C@H:31]([CH3:38])[CH2:32][CH2:33][CH2:34][CH:35]([CH3:37])[CH3:36])[CH2:22][CH2:23][CH2:24][C:25](=[O:27])[CH3:26].[CH3:4][C@H:3]([CH2:5][CH2:6][CH2:7][C@@H:8]([CH3:9])[CH2:10][CH2:11][CH2:12][CH:13]([CH3:15])[CH3:14])[CH2:2][CH2:1][CH2:16][C:17](=[O:19])[CH3:18].[CH3:4][C@H:3]([CH2:5][CH2:6][CH2:7][C@H:8]([CH3:9])[CH2:10][CH2:11][CH2:12][CH:13]([CH3:15])[CH3:14])[CH2:2][CH2:1][CH2:16][C:17](=[O:19])[CH3:18]